Natural Killer Cell Activity, Lymphocyte Proliferation, and Cytokine Profile in Tumor‐Bearing Mice Treated with MAPA, a Magnesium Aggregated Polymer from Aspergillus oryzae

References

• Chattopadhyay U., Bhattacharyya S., Chakrabarty N. G. Tumor associated macrophage mediated lysis of autologous tumor cells. Neoplasma 1986; 33: 157
   PubMed Web of Science ®Google Scholar
• Nelson D. S., Nelson M. Evasion of host defenses by tumor. Immunol. Cell Biol. 1987; 65: 287
   PubMed Web of Science ®Google Scholar
• Parhar R. S., Lala P. K. Changes in the host natural killer cell population in mice during tumor development. 1. Kinetics and in vivo significance. Cell. Immunol. 1985; 93: 250
   PubMedGoogle Scholar
• Parhar R. S., Lala P. K. Prostaglandin E2‐mediated inactivation of various killer lineage cells by tumor‐bearing host macrophages. J. Leukocyte Biol. 1988; 44: 185
   Web of Science ®Google Scholar
• Lopez D. M., Lopez‐Cepero M., Watson G. A., Ganju A., Sotomayor E. M., Fu Y‐X. Modulation of the immune system by mammary tumor‐derived factors. Cancer Invest. 1991; 9: 643
   PubMed Web of Science ®Google Scholar
• Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M., Forbes J. T. Anti‐transforming growth factor (TGF)‐β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF‐β interactions in human breast cancer progression. J. Clin. Invest. 1993; 92: 2569
   PubMed Web of Science ®Google Scholar
• Gosh P., Komschlies K. L., Cippitelli M., Longo D. L., Subleski J., Ye J., Sica A., Young H. A., Wiltrout R. H., Ochoa A. C. Loss of T‐helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 1995; 87: 1478
   PubMedGoogle Scholar
• Handel‐Fernandez M. E., Cheng X., Herbert L. M., Lopez D. M. Down‐regulation of IL‐12, not a shift from a T helper‐1 to a T helper‐2 phenotype, is responsible for impaired IFN‐γ production in mammary tumor‐bearing mice. J. Immunol. 1997; 158: 280
   PubMed Web of Science ®Google Scholar
• Huang M., Sharma S., Mao J. T., Dubinett S. M. Non‐small cell lung cancer‐derived soluble mediators and prostaglandin E2 enhanced peripheral blood lymphocyte IL‐10 transcription and protein production. J. Immunol. 1995; 157: 5512
   Google Scholar
• Ruiz de Morales J., Vélez D., Subiza J. L. Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony‐stimulating factors and without engagement of host T cells. Exp. Hematol. 1999; 27: 1757
   PubMed Web of Science ®Google Scholar
• Segura J. A., Barbero L. G., Márquez J. Early tumor effect on splenic Th lymphocytes in mice. FEBS Lett. 1997; 414: 1
   PubMed Web of Science ®Google Scholar
• Subiza J. L., Viñuela J. E., Rodriguez R., Gil J., Figueredo M. A., De la Concha E. G. Development of splenic natural suppressor (NS) cells in Ehrlich tumor‐bearing mice. Int. J. Cancer 1989; 44: 307
   PubMed Web of Science ®Google Scholar
• Parhar R. S., Lala P. K. Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity. Cell. Immunol. 1985; 93: 265
   PubMed Web of Science ®Google Scholar
• Chouaib S., Welte W., Martelsmann R., Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin‐2 production and down regulation of transferrin receptor expression. J. Immunol. 1985; 135: 1172
   PubMed Web of Science ®Google Scholar
• Segura J. A., Barbero L. G., Márquez J. Ehrlich ascites tumor unbalances splenic cell populations and reduces responsiveness of T cells to Staphylococcus aureus enterotoxin B stimulation. Immunol. Lett. 2000; 74: 111
   PubMed Web of Science ®Google Scholar
• Durán N., Nunes O. D.S. Characterization of an aggregated polymer from Penicillium sp. (PB‐73 strain). Brazil. J. Med. Biol. Res. 1990; 23: 1289
   PubMed Web of Science ®Google Scholar
• Durán N., Haun M., Pereira‐da‐Silva L., Pisani R., Pisani F. J.C., Souza‐Brito A. R.M., Mazetto M. N., Nunes O. D.S. Comparison of the antiviral activity and toxicity of the protein magnesium ammonium phospholinoleate anhydride polymer with other antiviral drugs. Brazil. J. Med. Biol. Res. 1990; 23: 1303
   PubMedGoogle Scholar
• Durán N., Souza‐Brito A. R.M., Haun M., De Oliveira J. A., Hetem S., Vargas L., Saavedra I., Justo G. Z. SB‐73‐immunostimulant. Drugs Fut. 1993; 18: 327
   Google Scholar
• Durán N., Justo G. Z., Souza‐Brito A. R.M., Rettori O., Vieira‐Matos A. N. SB‐73/MAPA: Protein magnesium ammonium phospholinoleate‐palmitoleate anhydride. Drugs Fut. 1997; 22: 454
   Google Scholar
• Melo A., Justo G. Z., Queiroz M. L.S. Stimulation of myelopoiesis in Listeria monocytogenes‐infected mice by an aggregated polymer isolated from Aspergillus oryzae. Human Exp. Toxicol. 2001; 20: 38
   PubMed Web of Science ®Google Scholar
• Durán N., Justo G. Z., Queiroz M. L.S., Vieira‐Matos A. N., Rettori O. New perspectives in immunomodulatory therapy of tumor induced by an extracellular aggregated polymer isolated from Aspergillus oryzae. Int. J. Mol. Med. 1999; 4: S49
   PubMedGoogle Scholar
• Justo G. Z., Durán N., Queiroz M. L.S. Myelopoietic response in tumor‐bearing mice by an aggregated polymer isolated from Aspergillus oryzae. Eur. J. Pharmacol. 2000; 388: 219
   PubMed Web of Science ®Google Scholar
• Olfert E. D., Cross B. M., McWilliam A. A. Guide to the Care and Use of Experimental Animals. Canadian Council on Animal Care, Ottawa 1993; 1: 1
   Google Scholar
• Viñuela J. E., Rodríguez R., Gil J., Coll J., De la Concha E. G., Subiza J. L. Antigen shedding vs. development of natural suppressor cells as mechanism of tumor escape in mice bearing Ehrlich tumor. Int. J. Cancer 1991; 47: 86
   PubMed Web of Science ®Google Scholar
• Kim S., Iizuka K., Aguila H. L., Weissman I. L., Yokoyama W. M. In vivo natural killer cell activities revealed by natural killer cell‐deficient mice. Proc. Natl. Acad. Sci. USA 2000; 97: 2731
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989; 47: 187
   PubMed Web of Science ®Google Scholar
• Scott P., Trinchieri G. The role of natural killer cells in host‐parasite interactions. Curr. Opin. Immunol. 1995; 7: 34
   PubMed Web of Science ®Google Scholar
• Djeu J. Y., Heinbaugh J. A., Holden H. T., Herberman R. B. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J. Immunol. 1979; 122: 175
   PubMed Web of Science ®Google Scholar
• Kuribayashi K., Gillis S., Kern D. E., Henney C. S. Murine NK cell cultures: effects of interleukin‐2 and interferon on cell growth and cytotoxic reactivity. J. Immunol. 1981; 126: 2321
   PubMed Web of Science ®Google Scholar
• Malkovsky M., Loveland M., North M., Asherson G., Gao L., Ward P., Fiers W. Recombinant interleukin‐2 directly augments the cytotoxicity of human monocytes. Nature 1987; 325: 262
   PubMed Web of Science ®Google Scholar
• Pace J. L., Russel S. W., Torres B. A., Johnson H. M., Gray P. W. Recombinant mouse γ interferon induces the priming step in macrophage activation for tumor cell killing. J. Immunol. 1983; 130: 2011
   PubMed Web of Science ®Google Scholar
• Yamamoto N., Zou J. P., Li X. F., Takenaka H., Noda S., Fujii T., Ono S., Kobayashi Y., Mukaida N., Matsushima K., Fujiwara H., Hamaoka T. Regulatory mechanisms for production of IFN‐γ and TNF by antitumor T‐cells or macrophages in the tumor‐bearing state. J. Immunol. 1995; 154: 2281
   PubMed Web of Science ®Google Scholar
• Hefeneider S. H., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J. Immunol. 1983; 130: 222
   PubMed Web of Science ®Google Scholar
• Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin‐2 augments natural killer cell activity. Nature 1981; 291: 335
   PubMed Web of Science ®Google Scholar
• Misawa E., Sakurai T., Yamada M., Hayasawa H., Motoyoshi K. Effects of macrophage colony‐stimulating factor and interleukin‐2 administration on NK1.1+ cells in mice. Int. J. Immunopharmacol. 2000; 22: 967
   PubMed Web of Science ®Google Scholar
• Sayers T. J., Wiltrout R. H. Differing roles for interleukin 2 and interferon γ in the augmentation of mouse peritoneal natural killer cell activity in vivo. Natural Killer Cells and Host Defenses, E. W. Ades, C. Lopez. S. Karger, Basel, AG 1989; 88
   Google Scholar
• Young H. A., Ortaldo J. R. One‐signal requirement for interferon‐γ production by human large granular lymphocytes. J. Immunol. 1987; 139: 724
   PubMed Web of Science ®Google Scholar
• Allavena P., Scala G., Djeu J. Y., Procopio A. D., Oppenheim J. S., Herberman R. B., Ortaldo J. R. Production of multiple cytokines by clones of human large granular lymphocytes. Cancer Immunol. Immunother. 1985; 19: 121
   PubMed Web of Science ®Google Scholar
• Svedersky L. P., Nedwin G. E., Goeddel D. V., Palladino M. A., Jr. Interferon‐γ enhances induction of lymphotoxin in recombinant interleukin 2‐stimulated peripheral blood mononuclear cells. J. Immunol. 1985; 134: 1604
   PubMed Web of Science ®Google Scholar
• Ehrhardt R. O., Ludviksson B. R., Gray B., Neurath M., Strober W. Induction and prevention of chronic inflammation in IL‐2‐deficient mice. J. Immunol. 1997; 158: 566
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of cloned cDNA for human interleukin‐2. Nature 1983; 302: 305
   PubMed Web of Science ®Google Scholar
• Licastro F., Davis L. J., Morini M. C. Lectins and superantigens: membrane interactions of these compounds with T lymphocytes affect immune responses. Int. J. Biochem. 1993; 25: 845
   PubMedGoogle Scholar
• Elexpuru A., Martin‐Nieto J., Jimenez A., Gomez C., Villalobo A. Ehrlich ascites tumor cells produce a transforming growth factor‐beta (TGFβ)‐like activity but lack receptors with TGFβ‐binding capacity. Mol. Cell. Biochem. 1997; 170: 153
   PubMed Web of Science ®Google Scholar
• Stefanski H. E., Mathur A. Decreased expression and function of Vβ6+ and Vβ14+ T cells is associated with decreased Th1 cytokine production in mice with plasma cell tumors. Tumori 1996; 82: 22
   PubMedGoogle Scholar
• Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.‐F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor‐β‐induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor‐bearing state. J. Immunol. 1991; 146: 1077
   PubMed Web of Science ®Google Scholar
• Yssel H., De Wall Malefyt R., Roncarolo M., Abrams J. S., Lahesmaa R., Spits H., De Vries J. E. IL‐10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J. Immunol. 1992; 149: 2378
   PubMed Web of Science ®Google Scholar
• Howard M., O'Garra A. Biological properties of interleukin 10. Immunol. Today 1992; 13: 198
   PubMedGoogle Scholar
• Mehrotra P. T., Donnelly R. P., Wong S., Kanegane H., Geremew A., Mostowski H. S., Furuke K., Siegel J. P., Bloom E. T. Production of IL‐10 by human natural killer cells stimulated with IL‐2 and/or IL‐12. J. Immunol. 1998; 160: 2637
   PubMedGoogle Scholar
• Ding L., Shevach E. M. IL‐10 inhibits mitogen‐induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J. Immunol. 1992; 148: 3133
   PubMed Web of Science ®Google Scholar